<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The communication is summarizing results of study aimed to ascertain the efficacy of treatment with epoetin alpha in patients with different <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> and, at the same time to evaluate the impact of this treatment on quality of their lives </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment efficacy in separate patients of the monitored population has been evaluated not only according to <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level increase, but also according to its effect on erythrocyte products consumption needed to control anemic syndrome </plain></SENT>
<SENT sid="2" pm="."><plain>Overall 134 patients with different <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> were included in the evaluation </plain></SENT>
<SENT sid="3" pm="."><plain>Full-extended monitoring, i.e. at least 3-month treatment with epoetin alpha, was passed by 127 (94.8%) patients </plain></SENT>
<SENT sid="4" pm="."><plain>Favorable effect of epoetin alpha administration was most often reported in patients with <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (85.7%), Waldenstrom s <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">macroglobulinemia</z:e> (80%) and <z:hpo ids='HP_0005550'>chronic lymphatic leukemia</z:hpo> (76.7%) </plain></SENT>
<SENT sid="5" pm="."><plain>Conversely the lowest efficacy was reported in the group of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Administration of epoetin alpha within treatment of underlying <z:hpo ids='HP_0001903'>anemia</z:hpo> in numerous <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> represents suitable alternative to the substitution therapy via erythrocyte transfusions </plain></SENT>
<SENT sid="7" pm="."><plain>Approximately 75% of monitored patients showed improvement of life quality, in some cases irrespective of results of treatment of their underlying disorder </plain></SENT>
</text></document>